The positive relationship between increased levels of circulating triglycerides and
cardiovascular events has been observed for decades. Driven by genetic cohort studies …

Despite the success of LDL-lowering drugs in reducing cardiovascular disease (CVD), there
remains a large burden of residual disease due in part to persistent dyslipidemia …

Abstract Purpose of Review Despite significant progress in plasma lipid lowering strategies,
recent clinical trials highlight the existence of residual cardiovascular risk. Angiopoietin-like …

Angptl3 and apoC-III are novel targets in lipoprotein metabolism that reduce triglycerides
when inhibited. The expected CVD risk reduction may be mediated through reduced …

Abstract Purpose of Review The role of the inhibition of ANGPTL3 in severe or refractory
hypercholesterolemia is well documented, less in severe hyperTG. This review focuses on …

Introduction The prevalence of hypertriglyceridemia (HTG) is increasing. Elevated
triglyceride (TG) levels are associated with an increased cardiovascular disease (CVD) risk …

Abstract Purpose of Review Elevated low-density lipoprotein cholesterol (LDL-C) and
triglyceride-rich lipoproteins (TRLs) or remnants are important risk factors for the …

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and
mortality in developed nations. Therapeutic modulation of dyslipidemia by inhibiting 3 …

Background Epidemiologic and genomewide association studies have linked loss-of-
function variants in ANGPTL3, encoding angiopoietin-like 3, with low levels of plasma …

Background: Hypertriglyceridemia is associated with increased cardiovascular risk and may
be caused by impaired lipoprotein clearance. Angiopoietin-like protein 3 (ANGPTL3) inhibits …